Genovate Biotechnology Co Ltd Market Cap ($115.03 Million)
Market Cap & Net Worth: Genovate Biotechnology Co Ltd (4130)
Genovate Biotechnology Co Ltd market cap. Genovate Biotechnology Co Ltd (TWO:4130) has a market capitalization of $115.03 Million (NT$3.65 Billion) as of November 6, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #18460 globally and #1001 in its home market, demonstrating a -5.15% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Genovate Biotechnology Co Ltd's stock price NT$26.70 by its total outstanding shares 136750000 (136.75 Million). Also see 4130 cash flow metrics for how efficiently the company converts equity into cash flow.
Genovate Biotechnology Co Ltd Market Cap History (2015–2026)
Genovate Biotechnology Co Ltd market cap history from 2015 to 2026. Data shows change from $230.84 Million to $115.03 Million (-1.91% CAGR). Check Genovate Biotechnology Co Ltd (4130) stock price for real-time trading data and today's change.
Genovate Biotechnology Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Genovate Biotechnology Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 4130 net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.24x
Genovate Biotechnology Co Ltd's market cap is 0.24 times its annual revenue
Latest Price to Earnings (P/E) Ratio
10.22x
Genovate Biotechnology Co Ltd's market cap is 10.22 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $138.97 Million | $411.20 Million | $39.21 Million | 0.34x | 3.54x |
| 2017 | $118.84 Million | $408.27 Million | $148.97 Million | 0.29x | 0.80x |
| 2018 | $101.46 Million | $455.80 Million | $57.85 Million | 0.22x | 1.75x |
| 2019 | $95.15 Million | $465.76 Million | $34.05 Million | 0.20x | 2.79x |
| 2020 | $117.00 Million | $472.72 Million | $38.73 Million | 0.25x | 3.02x |
| 2021 | $101.05 Million | $434.25 Million | $372.00K | 0.23x | 271.65x |
| 2022 | $134.28 Million | $438.76 Million | -$12.32 Million | 0.31x | N/A |
| 2023 | $110.53 Million | $528.51 Million | $29.33 Million | 0.21x | 3.77x |
| 2024 | $89.61 Million | $510.86 Million | $25.70 Million | 0.18x | 3.49x |
| 2025 | $119.34 Million | $492.41 Million | $11.68 Million | 0.24x | 10.22x |
Competitor Companies of 4130 by Market Capitalization
Companies near Genovate Biotechnology Co Ltd in the global market cap rankings as of November 6, 2026. Also see Genovate Biotechnology Co Ltd asset portfolio for a full breakdown of the balance sheet.
Key companies related to Genovate Biotechnology Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Genovate Biotechnology Co Ltd (2015–2026)
Market capitalization of Genovate Biotechnology Co Ltd from 2015 to today. Between 2015 and today, Genovate Biotechnology Co Ltd's market cap moved from $230.84 Million to $ 115.03 Million, with a yearly change of -1.91%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$115.03 Million | -3.61% |
| 2025 | NT$119.34 Million | +33.17% |
| 2024 | NT$89.61 Million | -18.92% |
| 2023 | NT$110.53 Million | -17.69% |
| 2022 | NT$134.28 Million | +32.88% |
| 2021 | NT$101.05 Million | -13.63% |
| 2020 | NT$117.00 Million | +22.96% |
| 2019 | NT$95.15 Million | -6.22% |
| 2018 | NT$101.46 Million | -14.62% |
| 2017 | NT$118.84 Million | -14.49% |
| 2016 | NT$138.97 Million | -39.80% |
| 2015 | NT$230.84 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Genovate Biotechnology Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $115.03 Million USD |
| MoneyControl | $115.03 Million USD |
| MarketWatch | $115.03 Million USD |
| marketcap.company | $115.03 Million USD |
| Reuters | $115.03 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Genovate Biotechnology Co Ltd
Genovate Biotechnology Co., Ltd. engages in the research, development, manufacture, production, and sale of products to prevent and treat diseases caused by viruses and bacteria in Taiwan. It provides drugs, APIs, intermediates, and release agents for the treatment of cardiovascular, esophageal, gastrointestinal, cancer, and autoimmune diseases; and controlled-release dosage forms of Western medi… Read more